1.35%| Prev Close: | 4.30 |
|---|---|
| Open: | 4.22 |
| Bid: | 3.64 x 300 |
| Ask: | N/A |
| 1y Target Est: | 6.25 |
| Beta: | 1.68 |
| Next Earnings Date: | N/A |
| Day's Range: | 4.21 - 4.52 |
|---|---|
| 52wk Range: | 2.11 - 4.52 |
| Volume: | 971,062 |
| Avg Vol (3m): | 551,138 |
| Market Cap: | 366.45M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.16 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Immunomedics to Present at Wells Fargo Securities 2013 Healthcare ConferenceGlobeNewswire(Fri, Jun 14)
- Update on UCB Lupus CandidateZacks(Thu, Jun 13)
- Immunomedics Presents Epratuzumab's Mechanism of Action in Systemic Lupus ErythematosusGlobeNewswire(Thu, Jun 13)
- Immunomedics Reports That UCB Announces New Results From Phase 2B Open-Label Extension Study Evaluating the Long-Term Effects of Epratuzumab in SLEGlobeNewswire(Thu, Jun 13)
- Immunomedics Reports Progress With Labeling Proteins, Including Antibodies, for Improved PET ImagingGlobeNewswire(Wed, Jun 12)
- Combination of 90Y-Epratuzumab and Veltuzumab is Active in Non-Hodgkin LymphomaGlobeNewswire(Tue, Jun 11)
- Immunomedics: Epratuzumab study shows improvement of therapy after R-CHOPtheflyonthewall.com(Mon, Jun 10)
- 90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOPGlobeNewswire(Mon, Jun 10)
- Immunomedics Develops Novel Dual System for Tumor Detection and ImagingGlobeNewswire(Mon, Jun 10)
- New Data From Epratuzumab to be Presented at EULAR 2013GlobeNewswire(Mon, Jun 10)
- January 2015 Options Now Available For Immunomedicsat Forbes(Tue, Jun 4)
- Immunomedics Announces Six Presentations at the Society of Nuclear Medicine and Molecular Imaging 2013 Annual MeetingGlobeNewswire(Mon, Jun 3)
- Coverage initiated on Immunomedics by WallachBethBriefing.com(Mon, Jun 3)
- This Week in Biotechat Motley Fool(Sat, Jun 1)
- Why Immunomedics Shares Soaredat Motley Fool(Thu, May 30)
Press Releases
- Immunomedics to Present at Wells Fargo Securities 2013 Healthcare ConferenceGlobeNewswire(Fri, Jun 14)
- Immunomedics Presents Epratuzumab's Mechanism of Action in Systemic Lupus ErythematosusGlobeNewswire(Thu, Jun 13)
- Immunomedics Reports That UCB Announces New Results From Phase 2B Open-Label Extension Study Evaluating the Long-Term Effects of Epratuzumab in SLEGlobeNewswire(Thu, Jun 13)
Reports
- IMMU: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(Jun 19)
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(Jun 19)
- IMMU - Immunomedics Inc - Downgraded to a Sell - Company Analysis and ASR Ranking...Alpha Street Research(Jun 18)